European Union - English - EMA (European Medicines Agency)

ge healthcare as - mangafodipir trisodium - magnetic resonance imaging - contrast media - this medicinal product is for diagnostic use only.contrast medium for diagnostic magnetic resonance imaging (mri) for the detection of lesions of the liver suspected to be due to metastatic disease or hepatocellular carcinomas. as an adjunct to mri to aid in the investigation of focal pancreatic lesions.

European Union - English - EMA (European Medicines Agency)

ge healthcare b.v. - ioflupane (123l) - tomography, emission-computed, single-photon; lewy body disease; parkinson disease; alzheimer disease - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.datscan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. datscan is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy.in adult patients, to help differentiate probable dementia with lewy bodies from alzheimer’s disease. datscan is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Ireland - English - HPRA (Health Products Regulatory Authority)

orpha-devel handels und vertriebs gmbh - naloxone hydrochloride - solution for injection/infusion - 400 microgram(s)/millilitre - antidotes; naloxone

European Union - English - EMA (European Medicines Agency)

biofrontera bioscience gmbh - 5-aminolevulinic acid hydrochloride - keratosis, actinic; carcinoma, basal cell - antineoplastic agents - treatment of actinic keratosis of mild to moderate severity on the face and scalp (olsen grade 1 to 2; see section 5.1) and of field cancerization in adults.treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults.

Malta - English - Medicines Authority

orpha-devel handels und vertriebs gmbh wintergasse 85/1b, a-3002 purkersdorf, austria - treprostinil sodium - solution for infusion - treprostinil sodium 1 mg/ml - antithrombotic agents

Malta - English - Medicines Authority

orpha-devel handels und vertriebs gmbh wintergasse 85/1b, a-3002 purkersdorf, austria - treprostinil sodium - solution for infusion - treprostinil sodium 2.5 mg/ml - antithrombotic agents

Malta - English - Medicines Authority

orpha-devel handels und vertriebs gmbh wintergasse 85/1b, a-3002 purkersdorf, austria - treprostinil sodium - solution for infusion - treprostinil sodium 5 mg/ml - antithrombotic agents

Malta - English - Medicines Authority

orpha-devel handels und vertriebs gmbh wintergasse 85/1b, a-3002 purkersdorf, austria - treprostinil sodium - solution for infusion - treprostinil sodium 10 mg/ml - antithrombotic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

orpha-devel handels und vertriebs gmbh - treprostinil - solution for infusion - 1 milligram(s)/millilitre - treprostinil

Ireland - English - HPRA (Health Products Regulatory Authority)

orpha-devel handels und vertriebs gmbh - treprostinil - solution for infusion - 10 milligram(s)/millilitre - treprostinil